JP2018021046A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018021046A5 JP2018021046A5 JP2017155657A JP2017155657A JP2018021046A5 JP 2018021046 A5 JP2018021046 A5 JP 2018021046A5 JP 2017155657 A JP2017155657 A JP 2017155657A JP 2017155657 A JP2017155657 A JP 2017155657A JP 2018021046 A5 JP2018021046 A5 JP 2018021046A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- pharmaceutical composition
- dosage form
- unit dosage
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 239000002552 dosage form Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- -1 1-naphth-2-ylethyl Chemical group 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000010425 asbestos Substances 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000034737 hemoglobinopathy Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 125000001326 naphthylalkyl group Chemical group 0.000 claims 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229910052895 riebeckite Inorganic materials 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91932307P | 2007-03-20 | 2007-03-20 | |
| US60/919,323 | 2007-03-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015211991A Division JP6373818B2 (ja) | 2007-03-20 | 2015-10-28 | ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018021046A JP2018021046A (ja) | 2018-02-08 |
| JP2018021046A5 true JP2018021046A5 (enExample) | 2018-06-14 |
| JP6448726B2 JP6448726B2 (ja) | 2019-01-09 |
Family
ID=39719168
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009554563A Withdrawn JP2010522170A (ja) | 2007-03-20 | 2008-03-19 | ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
| JP2014129790A Active JP5927241B2 (ja) | 2007-03-20 | 2014-06-25 | ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
| JP2015211991A Active JP6373818B2 (ja) | 2007-03-20 | 2015-10-28 | ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
| JP2017155657A Active JP6448726B2 (ja) | 2007-03-20 | 2017-08-10 | ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009554563A Withdrawn JP2010522170A (ja) | 2007-03-20 | 2008-03-19 | ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
| JP2014129790A Active JP5927241B2 (ja) | 2007-03-20 | 2014-06-25 | ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
| JP2015211991A Active JP6373818B2 (ja) | 2007-03-20 | 2015-10-28 | ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (6) | US8153659B2 (enExample) |
| EP (2) | EP3101017B1 (enExample) |
| JP (4) | JP2010522170A (enExample) |
| KR (3) | KR101791757B1 (enExample) |
| CN (2) | CN101679380A (enExample) |
| AR (1) | AR065810A1 (enExample) |
| AU (1) | AU2008229383B2 (enExample) |
| BR (1) | BRPI0809011A8 (enExample) |
| CA (1) | CA2681633C (enExample) |
| CL (1) | CL2008000805A1 (enExample) |
| CO (1) | CO6231033A2 (enExample) |
| CR (2) | CR11036A (enExample) |
| EC (1) | ECSP099663A (enExample) |
| ES (2) | ES2734253T3 (enExample) |
| IL (1) | IL200990A (enExample) |
| MX (1) | MX2009010082A (enExample) |
| MY (1) | MY180812A (enExample) |
| NI (1) | NI200900170A (enExample) |
| NZ (2) | NZ579890A (enExample) |
| PE (1) | PE20081894A1 (enExample) |
| RU (1) | RU2471794C2 (enExample) |
| UA (1) | UA97976C2 (enExample) |
| UY (1) | UY30977A1 (enExample) |
| WO (1) | WO2008115516A2 (enExample) |
| ZA (1) | ZA200906497B (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2929331B2 (ja) * | 1990-07-18 | 1999-08-03 | 丸善石油化学株式会社 | トラクションドライブ用流体 |
| CN101111234A (zh) * | 2004-12-01 | 2008-01-23 | 细胞基因公司 | 包含免疫调节化合物的组合物及其治疗免疫缺陷疾病的用途 |
| KR101791757B1 (ko) | 2007-03-20 | 2017-10-30 | 셀진 코포레이션 | 4'-ｏ-치환된 아이소인돌린 유도체 및 이를 포함하는 조성물 및 이의 사용 방법 |
| US7964354B2 (en) * | 2007-12-20 | 2011-06-21 | Celgene Corporation | Use of micro-RNA as a biomarker of immunomodulatory drug activity |
| AU2010327936B2 (en) | 2009-12-11 | 2015-08-20 | Nono Inc. | Agents and methods for treating ischemic and other diseases |
| PL2536706T3 (pl) * | 2010-02-11 | 2017-10-31 | Celgene Corp | Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania |
| AU2013245487B2 (en) * | 2010-02-11 | 2016-03-10 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| AU2016203826B2 (en) * | 2010-02-11 | 2018-05-17 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| WO2012135299A1 (en) | 2011-03-28 | 2012-10-04 | Deuteria Pharmaceuticals Inc | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| EP2720695A4 (en) * | 2011-06-15 | 2014-11-12 | Nono Inc | ACTIVE AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES |
| CN102731853B (zh) * | 2012-06-28 | 2013-11-27 | 芜湖宏达橡塑阀门制造有限公司 | 耐油橡胶 |
| CN102731850B (zh) * | 2012-06-28 | 2013-11-27 | 芜湖宏达橡塑阀门制造有限公司 | 耐油耐磨橡胶 |
| CN102731851B (zh) * | 2012-06-28 | 2013-11-27 | 芜湖宏达橡塑阀门制造有限公司 | 一种耐油橡胶 |
| US9133161B2 (en) * | 2012-07-27 | 2015-09-15 | Celgene Corporation | Processes for preparing isoindoline-1,3-dione compounds |
| US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
| PT2882441T (pt) | 2012-08-09 | 2020-06-29 | Celgene Corp | Tratamento de doenças associadas à imunidade e inflamatórias |
| SG11201500984QA (en) | 2012-08-09 | 2015-04-29 | Celgene Corp | Processes for the preparation of (s)-3-4-((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6-dione and pharmaceutically acceptable forms thereof |
| JP6347782B2 (ja) * | 2012-08-09 | 2018-06-27 | セルジーン コーポレイション | ３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンを使用する癌の治療方法 |
| US9540340B2 (en) | 2013-01-14 | 2017-01-10 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same |
| US9695145B2 (en) | 2013-01-22 | 2017-07-04 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| US9242966B2 (en) | 2013-03-11 | 2016-01-26 | Bristol-Myers Squibb Company | Phthalazines as potassium ion channel inhibitors |
| US9290475B2 (en) | 2013-03-14 | 2016-03-22 | Deuterx, Llc | 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same |
| AU2014254056B2 (en) | 2013-04-17 | 2019-06-06 | Signal Pharmaceuticals, Llc | Combination therapy comprising a TOR kinase inhibitor and an IMiD compound for treating cancer |
| UA117141C2 (uk) | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
| ES2969532T3 (es) | 2014-05-19 | 2024-05-21 | Celgene Corp | 3-(4-((4-(Morfolinometil-bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona para el tratamiento de lupus eritematoso sistémico |
| NZ731789A (en) * | 2014-10-30 | 2019-04-26 | Kangpu Biopharmaceuticals Ltd | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| US10231959B2 (en) | 2016-03-23 | 2019-03-19 | Louis Habash | Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide |
| US20180078539A1 (en) | 2016-03-23 | 2018-03-22 | Louis Habash | T-cell regulation in t-cell mediated diseases by reducing pathogenic function of th17 in a human subject through treatment with a nitroxide |
| WO2017165572A1 (en) * | 2016-03-23 | 2017-09-28 | Louis Habash | Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide |
| US10159665B2 (en) | 2016-03-23 | 2018-12-25 | Louis Habash | Preventing amyloid plaque formation by treating a human subject with a nitroxide |
| ES2989988T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros heterorocíclicos para la degradación de proteínas diana |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| KR20220028178A (ko) * | 2016-12-16 | 2022-03-08 | 강푸 바이오파마슈티칼즈 리미티드 | 조성물, 이의 적용 및 치료 방법 |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| WO2019014100A1 (en) | 2017-07-10 | 2019-01-17 | Celgene Corporation | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF |
| CN111278816B (zh) | 2017-09-04 | 2024-03-15 | C4医药公司 | 二氢喹啉酮 |
| EP3679026A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Glutarimide |
| CN111315735B (zh) | 2017-09-04 | 2024-03-08 | C4医药公司 | 二氢苯并咪唑酮 |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
| CN111902141A (zh) | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
| EP3778590A4 (en) * | 2018-04-09 | 2021-12-22 | ShanghaiTech University | ANTI PROTEIN DEGRADATION COMPOUND, ANTITUMOR APPLICATION, INTERMEDIATE THEREOF, AND INTERMEDIATE USE |
| CN112312904B (zh) | 2018-04-16 | 2025-01-07 | C4医药公司 | 螺环化合物 |
| SG11202009237XA (en) | 2018-04-23 | 2020-10-29 | Celgene Corp | Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma |
| EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
| BR122022012697B1 (pt) | 2018-07-10 | 2023-04-04 | Novartis Ag | Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit |
| WO2020064002A1 (zh) | 2018-09-30 | 2020-04-02 | 中国科学院上海药物研究所 | 异吲哚啉类化合物、其制备方法、药物组合物及用途 |
| US11529339B2 (en) | 2018-10-01 | 2022-12-20 | Celgene Corporation | Combination therapy for the treatment of cancer |
| WO2020092950A1 (en) * | 2018-11-01 | 2020-05-07 | Northwestern University | Targeting pleckstrin-2 for treating cancer |
| EP3891128A4 (en) * | 2018-12-05 | 2022-08-17 | Vividion Therapeutics, Inc. | SUBSTITUTED ISOINDOLINONES AS MODULATORS OF CEREBLON-MEDIATED NEOSUBSTRATE RECRUITMENT |
| CN111285850B (zh) | 2018-12-06 | 2022-04-22 | 中国科学院上海药物研究所 | 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用 |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| WO2020172418A1 (en) * | 2019-02-22 | 2020-08-27 | Elkem Silicones USA Corp. | Drug delivery silicone compositon to improve active ingredient elution |
| WO2020181232A1 (en) | 2019-03-06 | 2020-09-10 | C4 Therapeutics, Inc. | Heterocyclic compounds for medical treatment |
| CN111747924B (zh) * | 2019-03-29 | 2023-11-10 | 华东师范大学 | 一类来那度胺/泊马度胺类似物及其应用 |
| KR20210152515A (ko) | 2019-04-12 | 2021-12-15 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| SG11202110085TA (en) | 2019-05-31 | 2021-10-28 | Sichuan Haisco Pharmaceutical Co Ltd | Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof |
| CN112321566B (zh) | 2019-08-05 | 2022-06-10 | 上海科技大学 | Egfr蛋白降解剂及其抗肿瘤应用 |
| KR102833592B1 (ko) * | 2020-02-25 | 2025-07-15 | 상하이테크 유니버시티 | 글루타르이미드 골격을 기초로 하는 화합물 및 그 응용 |
| KR20230004493A (ko) * | 2020-04-17 | 2023-01-06 | 에시언트 파마슈티컬스 인코포레이티드 | Mas-관련 G-단백질 수용체 X4의 조절제 및 관련 제품 및 방법 |
| JP2023534528A (ja) * | 2020-07-20 | 2023-08-09 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 硫黄含有イソインドリン系誘導体、その調製方法及びその医薬的応用 |
| CN116669736B (zh) * | 2021-01-05 | 2025-11-11 | 江苏恒瑞医药股份有限公司 | 稠杂环基取代的环己二酰亚胺衍生物、其制备方法及其在医药上的应用 |
| MX2023008296A (es) | 2021-01-13 | 2023-09-29 | Monte Rosa Therapeutics Inc | Compuestos de isoindolinona. |
| CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
| US20250154126A1 (en) | 2022-01-19 | 2025-05-15 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Crystalline form of sulfur-containing isoindoline derivative |
| EP4536656A1 (en) | 2022-06-06 | 2025-04-16 | C4 Therapeutics, Inc. | Bicyclic-substituted glutarimide cereblon binders |
| AR130961A1 (es) | 2022-11-04 | 2025-02-05 | Bristol Myers Squibb Co | Compuestos y su uso para el tratamiento de hemoglobinopatías |
| CN116675786A (zh) * | 2023-07-10 | 2023-09-01 | 盐城师范学院 | 一种靶向传递喜树碱的环糊精超分子药物及其制备方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| US5001116A (en) | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
| KR19980074060A (ko) * | 1997-03-21 | 1998-11-05 | 김윤배 | 신규한 치환된 3,4-디알콕시페닐 유도체 |
| ES2243052T3 (es) * | 1998-03-16 | 2005-11-16 | Celgene Corporation | Derivados de la 2- (2,6-dioxopiperidin-3-il) isoindolina, su preparacion y su empleo como inhibidores de las citocinas inflamatorias. |
| US6458810B1 (en) * | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| US7320992B2 (en) * | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
| CA2808646C (en) * | 2003-09-17 | 2016-08-23 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Thalidomide analogs as tnf-alpha modulators |
| GB0324790D0 (en) * | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Amide derivatives |
| CN101111234A (zh) | 2004-12-01 | 2008-01-23 | 细胞基因公司 | 包含免疫调节化合物的组合物及其治疗免疫缺陷疾病的用途 |
| MY140868A (en) * | 2004-12-24 | 2010-01-29 | Astrazeneca Ab | Amide derivatives |
| KR101791757B1 (ko) * | 2007-03-20 | 2017-10-30 | 셀진 코포레이션 | 4'-ｏ-치환된 아이소인돌린 유도체 및 이를 포함하는 조성물 및 이의 사용 방법 |
-
2008
- 2008-03-19 KR KR1020157009558A patent/KR101791757B1/ko active Active
- 2008-03-19 CA CA2681633A patent/CA2681633C/en active Active
- 2008-03-19 AR ARP080101179A patent/AR065810A1/es not_active Application Discontinuation
- 2008-03-19 RU RU2009138500/04A patent/RU2471794C2/ru active
- 2008-03-19 CN CN200880016715A patent/CN101679380A/zh active Pending
- 2008-03-19 JP JP2009554563A patent/JP2010522170A/ja not_active Withdrawn
- 2008-03-19 WO PCT/US2008/003602 patent/WO2008115516A2/en not_active Ceased
- 2008-03-19 MY MYPI20093935A patent/MY180812A/en unknown
- 2008-03-19 ES ES16170365T patent/ES2734253T3/es active Active
- 2008-03-19 EP EP16170365.7A patent/EP3101017B1/en active Active
- 2008-03-19 US US12/077,715 patent/US8153659B2/en active Active
- 2008-03-19 NZ NZ579890A patent/NZ579890A/en not_active IP Right Cessation
- 2008-03-19 BR BRPI0809011A patent/BRPI0809011A8/pt not_active Application Discontinuation
- 2008-03-19 UA UAA200910592A patent/UA97976C2/ru unknown
- 2008-03-19 EP EP08726977.5A patent/EP2142534B1/en active Active
- 2008-03-19 ES ES08726977.5T patent/ES2601131T3/es active Active
- 2008-03-19 KR KR1020097021797A patent/KR20090121400A/ko not_active Ceased
- 2008-03-19 NZ NZ599199A patent/NZ599199A/xx not_active IP Right Cessation
- 2008-03-19 MX MX2009010082A patent/MX2009010082A/es active IP Right Grant
- 2008-03-19 AU AU2008229383A patent/AU2008229383B2/en active Active
- 2008-03-19 CN CN201310547773.7A patent/CN103641814A/zh active Pending
- 2008-03-19 KR KR1020177021704A patent/KR20170093996A/ko not_active Ceased
- 2008-03-20 CL CL2008000805A patent/CL2008000805A1/es unknown
- 2008-03-24 PE PE2008000525A patent/PE20081894A1/es not_active Application Discontinuation
- 2008-03-24 UY UY30977A patent/UY30977A1/es not_active Application Discontinuation
-
2009
- 2009-09-16 IL IL200990A patent/IL200990A/en not_active IP Right Cessation
- 2009-09-17 ZA ZA2009/06497A patent/ZA200906497B/en unknown
- 2009-09-18 NI NI200900170A patent/NI200900170A/es unknown
- 2009-09-21 CR CR11036A patent/CR11036A/es unknown
- 2009-09-30 EC EC2009009663A patent/ECSP099663A/es unknown
- 2009-09-30 CO CO09106869A patent/CO6231033A2/es not_active Application Discontinuation
-
2012
- 2012-03-01 US US13/410,216 patent/US8614328B2/en not_active Ceased
-
2013
- 2013-11-18 US US14/083,205 patent/US9181216B2/en active Active
-
2014
- 2014-06-25 JP JP2014129790A patent/JP5927241B2/ja active Active
- 2014-07-16 US US14/333,454 patent/USRE46639E1/en active Active
- 2014-08-01 CR CR20140368A patent/CR20140368A/es unknown
-
2015
- 2015-10-02 US US14/874,318 patent/US9920027B2/en active Active
- 2015-10-28 JP JP2015211991A patent/JP6373818B2/ja active Active
-
2017
- 2017-08-10 JP JP2017155657A patent/JP6448726B2/ja active Active
-
2018
- 2018-02-02 US US15/887,838 patent/US10385037B2/en active Active